Shrinks In Sneakers

Tag: esketamine

  • 🧠 Esketamine + Antidepressants in TRD: Does the Combo Matter?

    🧠 Esketamine + Antidepressants in TRD: Does the Combo Matter?

    📢 New data from a real-world study of 50,000+ patients with treatment-resistant depression (TRD) published in JAMA Psychiatry:

    📌 Study Question:
    Does combining esketamine with an SSRI or SNRI affect long-term outcomes in TRD?

    📊 Key Findings (5-Year Follow-Up):

    • ✅ Esketamine + SNRI:
       ↘️ Lower all-cause mortality
       ↘️ Fewer hospitalizations
       ↘️ Reduced depressive relapse
    • ✅ Esketamine + SSRI:
       ↘️ Lower incidence of suicide attempts
    • 🔒 Overall: Low rates of adverse outcomes in all groups

    💡 Clinical Implications:

    • Not all combinations are equal—pairing matters.
    • Esketamine + SNRI may be preferred for reducing relapse/mortality
    • Esketamine + SSRI may be considered in patients at risk for suicide
    • Personalized treatment decisions can enhance outcomes in TRD

    🔍 More than symptom relief—it’s about survival, stability, and safety.

  • 📌 CANMAT Guidelines for Depression: Evidence-Based Treatment Strategies

    📌 CANMAT Guidelines for Depression: Evidence-Based Treatment Strategies

    The CANMAT 2016 guidelines remain one of the most comprehensive, evidence-based frameworks for treating major depressive disorder (MDD). These guidelines emphasize a stepwise, individualized approach based on efficacy, safety, and patient preference. Here’s a breakdown of the key recommendations:

    🔹 First-Line Treatments

    ✅ Psychotherapy – Cognitive Behavioral Therapy (CBT), Interpersonal Therapy (IPT), and Mindfulness-Based CBT are recommended, especially for mild to moderate depression.
    ✅ Pharmacotherapy – SSRIs, SNRIs, bupropion, mirtazapine, and vortioxetine are all first-line antidepressantsbased on efficacy and tolerability.
    ✅ Neurostimulation – Electroconvulsive Therapy (ECT) and Repetitive Transcranial Magnetic Stimulation (rTMS) are considered first-line for severe or treatment-resistant depression (TRD).

    🔹 Second-Line Treatments

    🔸 Other antidepressants – Tricyclics (TCAs), trazodone, moclobemide, and some atypical antipsychotics (e.g., quetiapine XR, aripiprazole, brexpiprazole)
    🔸 Adjunctive strategies – Lithium, atypical antipsychotics, or combination antidepressant therapy for partial responders
    🔸 Ketamine/esketamine – Emerging evidence for TRD

    🔹 Third-Line & Beyond

    🔹 MAOIs (reserved for treatment-resistant cases)
    🔹 Novel agents (psilocybin, anti-inflammatory treatments) – Experimental but promising

    💡 Key Takeaways
    🔹 Personalized treatment is essential – factors like symptom profile, comorbidities, and patient preference influence the best approach.
    🔹 Combination strategies (meds + psychotherapy) often yield superior outcomes.
    🔹 Treatment-resistant depression requires a multimodal approach, including augmentation, switching strategies, and neurostimulation options.

    The CANMAT guidelines are a critical resource for clinicians, offering a structured approach to optimizing depression treatment. What are your go-to strategies for managing MDD? Let’s discuss!

    #DepressionTreatment #Psychiatry #CANMAT #MDD #Psychopharmacology